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Edited by Ned ManteiAbstract TNF-a, generated during the systemic inﬂammatory
response, triggers a wide range of biological activities that
mediate the neurologic manifestations associated with cancer
and infection. Since this cytokine regulates ion channels in vitro
(especially Kv1.3 and Kir2.1), we aimed to study Kv1.3 and
Kir2.1 expression in brain in response to in vivo systemic
inﬂammation. Cancer-induced cachexia and LPS administration
increased plasma TNF-a. Kv1.3 and Kir2.1 expression was
impaired in brain during cancer cachexia. However, LPS
treatment induced Kv1.3 and downregulated Kir2.1 expression,
and TNF-a administration mimicked these results. Experiments
using TNF-a double receptor knockout mice demonstrated that
the systemic inﬂammatory response mediates Kþ channel
regulation in brain via TNF-a-dependent and -independent
redundant pathways. In summary, distinct neurological altera-
tions associated with systemic inﬂammation may result from the
interaction of various cytokine pathways tuning ion channel
expression in response to neurophysiological and neuroimmuno-
logical processes.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Systemic inﬂammation represents a pleiotropic mechanism
generated in response to a number of body insults. Trauma,
AIDS, drug abuse, infection and cancer are often associated
with this pathological condition through the production of
inﬂammatory cytokines, TNF-a being one of the most rele-
vant. The administration of lipopolysaccharide (LPS) or pro-
inﬂammatory cytokines to animals mimics several catabolic
aspects of cancer-induced cachexia [1,2]. Cytokines act in
paracrine, autocrine and intracrine manners, and are often* Corresponding author. Fax: +34-934021559.
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doi:10.1016/j.febslet.2004.07.030diﬃcult to detect in the circulation. In fact, paracrine inter-
actions are a predominant cytokine mode of action within
organs, including the brain. In the central nervous system, the
direct action of cytokines in neuronal cells either increases or
decreases neuronal activity, while in other nerve cell types, it
can activate an immunological/inﬂammatory response. In
certain pathophysiological conditions, cytokine cascades lead
to neurotoxicity and neurodegeneration [3].
LPS, a gram-negative bacterial endotoxin, has been exten-
sively used for experimental induction of an inﬂammatory
response; it causes anorexia and fever, and increases TNF-a
production in rodents [4,5]. On the other hand, experimentally
induced cancer-cachexia is a pathological state also charac-
terized by a signiﬁcant increase in TNF-a blood levels [6]. This
cytokine possesses a wide range of biological activities. In the
nervous system, TNF-a exerts cytotoxic eﬀects on oligoden-
drocytes and aﬀects myelin functions [7]. In addition, the
concentration of TNF-a in brain tissues or serum is enhanced
in neurodegenerative disorders such as Parkinson’s and Alz-
heimer’s diseases [8,9]. Thus, the central nervous system (CNS)
is a clear target for cytokines involved in the inﬂammatory
response. In this context, in vivo characterization of the mo-
lecular mechanisms responsible for the neurological manifes-
tations triggered by the systemic inﬂammatory response is a
key issue. One such mechanism involves the modulation of ion
channels.
Neuronal Kþ channels (KCh) form a large and diverse
group that governs many physiological functions, e.g., resting
membrane potential, action potential duration and frequency,
and neurotransmitter release [10]. Voltage-dependent currents
are mainly mediated by Shaker-like potassium channels (Kv),
whereas inward currents are conducted by inward rectiﬁer Kþ
channels (Kir). In CNS excitability, Kv repolarizes the mem-
brane potential following a depolarizing stimulus. However,
Kir stabilizes the resting membrane potential near the Kþ
equilibrium potential and mediates Kþ transport across
membranes [10].
The few in vitro studies that have analyzed the physiological
eﬀects of TNF-a on KCh show controversial results [11–14]. In
this regard, we have described how Kv1.3 and Kir2.1 are
regulated by LPS via TNF-a-dependent and -independent
mechanisms in macrophages [15]. We have also reported thatblished by Elsevier B.V. All rights reserved.
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immunological response. Kv1.3 is involved in macrophage-
induced activation by LPS and TNF-a [15]. It is also present in
brain and given its biophysical activity, it has been related to
the control of the neuronal ﬁring pattern [16]. Moreover,
Kir2.1 is also widely expressed in nerve cells with a relevant
role in neuronal excitability and glial Kþ transport [17]. Al-
though experimental cancer-induced cachexia downregulates
the expression of Kv channels (i.e., Kv1.3) in brain, there is no
information on Kir2.1 regulation or whether impaired Kv
expression is directly related to the generation of a systemic
inﬂammatory response [6].
Bearing all this in mind, we aimed to study the expression of
the strongly inwardly rectifying potassium channel Kir2.1 in
experimental cancer-induced cachexia and to evaluate whether
KCh regulation is related to the rise in blood TNF-a levels
during the systemic inﬂammatory response in vivo. In this
context, since no in vivo studies have been reported, we
followed several related approaches: (i) experimental cancer-
induced cachexia by a rapidly growing tumor; (ii) TNF-a
chronic administration and (iii) LPS administration using
wild-type and TNF-a double receptor knockout (TNF-a RI/
II-KO) mice. We show that the systemic inﬂammatory re-
sponse regulates Kv1.3 and Kir2.1 channels diﬀerentially and
that this modulation is mediated via TNF-a-dependent and
-independent redundant pathways. Our results suggest that the
diﬀerential expression of KCh subunits in the brain is crucial
to achieving the correct neural activity in the systemic
inﬂammatory response.2. Materials and methods
2.1. Animals and experimental design
Several experimental groups of at least ﬁve animals each were used.
Animals from Iﬀa-Credo (France) were fed ad libitum on a regular
chow diet with free access to drinking water.
Experimental cancer-induced cachexia: Female Wistar rats (200 g)
were injected intraperitoneally with a Yoshida AH-130 ascites hepa-
toma cell suspension (approx. 108 cells in 2 ml). Control rats were
injected with 0.9% (w/v) NaCl solution (physiological saline) as de-
scribed [6]. All extractions were performed 7 days after tumor trans-
plantation.
TNF-a treatment: Female Wistar rats (200 g) were injected twice a
day with recombinant-derived human TNF-a (50 lg/kg, i.p.) for 4 days
[18]. Control animals followed the same schedule receiving saline.
LPS treatment: C57BL/6 mice of about 20 weeks of age were used.
TNF-a RI/II-KO mice kindly provided by Hoﬀmann–LaRoche were
generated and characterized as reported [19,20]. Puriﬁed LPS (Esche-
richia coli endotoxin 0111:B4) was dissolved in pyrogen-free saline.
Animals were injected intraperitoneally at a dose of 2.5 mg/kg. Ani-
mals kept at thermoneutral temperature (30 C) developed fever 23 h
after the LPS injection (data not shown, [21]). Another set of wild type
and TNF-a RI/II-KO mice was used to administrate TNF-a (100 lg/
kg, i.v.) as previously described [22–24]. In all cases, control mice re-
ceived sterile saline.2.2. Samples and TNF-a measurements
Blood was collected from killed animals and the plasma was ob-
tained by centrifugation and quickly frozen. In all cases, tissue samples
were removed and weighed at the end of the treatment. The brain and
the heart were immediately frozen with liquid nitrogen and maintained
at )80 C until use. Animal handling procedures were approved by the
Ethics committee of the University of Barcelona.
Plasma TNF-a was measured by using an ELISA test (Genzyme
Corp.) following the manufacturer’s instructions.2.3. RNA extraction, cDNA probes, constructs, reverse
transcription-polymerase chain reaction (RT-PCR) and
Southern blot
Total RNA from brain and heart was isolated using Tripure (Roche
Diagnostics). Samples were further treated with the DNA-free kit from
Ambion Inc. to remove DNA. RNA from at least ﬁve animals was
analyzed per group.
Ready-to-Go RT-PCR Beads (Amersham Pharmacia Biotech) were
used in a one-step RT-PCR. Total RNA and Kv1.3, Kir2.1 and 18S
primers were added to the beads as described [15]. A range of PCR
cycles and RNA dilutions from each independent sample were per-
formed to obtain an exponential phase of amplicon production (data
not shown) as described [25]. The same independent RNA aliquot was
used to analyze the KCh mRNA expression and the respective amount
of 18S rRNA.
Once the exponential phase of the amplicon production had been
determined, the speciﬁcity of each product was conﬁrmed in test RT-
PCRs using the appropriate cDNA probe in a Southern blot analysis
[26]. PCR-generated KCh cDNA probes from mouse brain were used
as probes as described [15]. At least three ﬁlters were prepared from
independent samples and representative blots are shown. The densi-
tometric analysis of the blots was performed using Phoretix software
(Nonlinear Dynamics). Results are the meansS.E.M. of each ex-
perimental group. Where indicated, statistical analysis by Student’s t
test was performed.
2.4. Membrane preparation and Western blot analysis
Brain samples were homogenized in 320 mM sucrose, supplemented
with 1 lg/ml aprotinin, 1 lg/ml leupeptin, 86 lg/ml iodoacetamide and
1 mM phenylmethylsulfonyl ﬂuoride as protease inhibitors in a glass
homogenizer. An enriched membrane preparation was obtained [27].
Brieﬂy, homogenates were centrifuged at 2000 · g for 5 min and the
supernatant was further centrifuged at 100 000 · g for 1 h. The pellet
was resuspended in the same solution and protein content was deter-
mined by Bio-Rad Protein Assay (Bio-Rad). Samples were aliquoted
and stored at )80 C.
Crude membrane protein samples (50 lg) were boiled in Laemmli
SDS loading buﬀer and separated on 10% SDS–PAGE. They were
transferred to nitrocellulose membranes (Immobilon-P, Millipore) and
blocked in 5% dried milk-supplemented 0.2% Tween 20 PBS before
immunoreaction. To monitor Kv1.3 and Kir2.1 expression, rabbit
polyclonal antibodies (Alomone Labs) were used. As a loading and
transfer control, a monoclonal anti-b-actin antibody (Sigma) was used.3. Results and discussion
The generation and release of proinﬂammatory cytokines
are among the main features of the systemic inﬂammatory
response. In particular, TNF-a is a pleiotropic cytokine that
plays a pivotal role in inﬂammatory diseases of the central
nervous system [3,11,12]. It is generated mostly by macro-
phages in response to an insult and is a major mediator of the
septic shock syndrome induced by either LPS or bacterial su-
perantigens [20]. In addition, high levels of TNF-a have also
been detected in neurodegenerative disorders [8,9]. Bearing this
in mind, the aim of the present work was to analyze the po-
tential role of TNF-a regulating KCh expression in brain
during a systemic inﬂammatory response.
The results presented in Fig. 1 show plasma TNF-a con-
centration in two models of systemic inﬂammatory response, a
model of experimental induced cancer-cachexia and in another
model involving LPS administration. Rats that eﬃciently de-
veloped the Yoshida AH-130 tumor showed an increase in
plasma cytokine concentration. On the other hand, LPS-trea-
ted mice also showed high TNF-a levels in plasma, as reported
elsewhere [28,29]. During cancer cachexia, the systemic TNF-a
concentration increases concomitantly with tumor progres-
sion, while LPS rapidly increases plasma TNF-a within the
ﬁrst 2–3 h with a progressive decay over the next 24 h (data not
Fig. 1. Experimental cancer cachexia and LPS administration in-
creased plasma TNF-a levels. (A) Wistar rats were injected intraperi-
toneally with saline (Crtl) or Yoshida AH-130 ascites hepatoma cell
suspension (Tumor) as described in Section 2. Samples were collected 7
days after tumor transplantation. (B) Some C57BL/6 mice were in-
jected intraperitoneally (2.5 mg/kg) with puriﬁed LPS in saline (LPS).
Control mice (Crtl) received an equivalent volume of sterile saline
as described in Section 2. Blood samples were collected 3 h after
LPS administration. Values are means S.E.M. of ﬁve animals.
*** P < 0:001 vs. Crtl (Student’s t test).
Fig. 2. Expression of Kv1.3 and Kir2.1 in brain and heart from animals und
with either saline (Control) or the Yoshida AH-130 ascites hepatoma cell sus
protein samples were analyzed for Kþ channel expression after 7 days of tum
PCR on 0.25 lg and 1 lg for brain and heart, respectively, and 30 cycles for
conditions were at the exponential phase of the amplicon production as des
resentative blots are shown. Arbitrary unit (AU) values the meansS.E.M.
bearing animals (T). *P < 0:05; **P < 0:01; ns, not signiﬁcant vs. control (S
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signiﬁcant rise in circulating TNF-a triggering the catabolic
inﬂammatory response.
Several neurodegenerative disorders, such as Parkinson’s
and Alzheimer’s diseases share a systemic inﬂammatory re-
sponse, similar to that we observed [8,9]. In these pathological
conditions, nerve KCh are implicated in the neural response.
Thus, b-amyloid peptide regulates the expression of KCh in
microglia by upregulating Kv1.3 and Kv1.5 with no eﬀects on
Kir channels [30]. Kv channels (i.e., Kv1.3) repolarize the
membrane potential after depolarization. However, Kir
channels stabilize the resting membrane potential near the Kþ
equilibrium potential and mediate Kþ transport across mem-
branes. This role is crucial in the case of the strongly inward
rectiﬁer Kir2.1, which participates in the intrusion of Kþ ions
released from nerve axons. An increase in extracellular Kþ
may induce uncontrolled hyperexcitability and abnormal
synchronization of neurons [17]. Experimental cancer cachexia
speciﬁcally downregulated Kir2.1 as observed with Kv1.3 [6,
Fig. 2]. Kv1.3 mRNA expression is impaired in the brain of
tumor-bearing animals [6]. Here, we conﬁrm and extend these
results by reporting a parallel decrease in Kv1.3 protein in
crude membrane samples from brain (Fig. 2B). The Kir2.1
downregulation observed in brain seems to be tissue-speciﬁc.
This result may seem puzzling, since cancer cachexia is char-er experimental cancer cachexia. At least ﬁve animals were inoculated
pension (Tumor) as described in Section 2. Total RNA and membrane
or growth. (A) Kir2.1 and Kv1.3 mRNA expression. Results from RT-
Kir2.1 and Kv1.3, and 0.1 lg and 10 cycles for 18S are shown. These
cribed in Section 2. (B) Kir2.1 and Kv1.3 Western blot analysis. Rep-
of at least four animals. Closed bars, Control (C); open bars, tumor-
tudent’s t test).
Fig. 3. Expression of Kv1.3 and Kir2.1 in brain from TNF-a-treated
animals. At least ﬁve animals were administered intraperitoneally with
either saline (control) or recombinant-derived human TNF-a (TNF-a)
for 4 days. Animals were administered in two daily injections of 50 lg/
kg (total dose of100 lg/kg per day) for 4 days as described in Section 2.
(A) Kir2.1 and Kv1.3 mRNA expression. Results from RT-PCR on
0.25 lg and 30 cycles for Kir2.1 and Kv1.3, and 0.1 lg and 10 cycles
for 18S are shown. These conditions were at the exponential phase of
amplicon production as described in Section 2. (B) Kir2.1 and Kv1.3
mRNA expression values derived from panel A. (C) Kir2.1 and Kv1.3
Western blot analysis. Representative blots are shown. (D) Kir2.1 and
Kv1.3 protein expression values derived from panel C. In all cases,
arbitrary units are standardized to the control value in the absence of
TNF-a. Values are meansS.E.M. of at least four animals. Closed
bars, control; open bars, TNF-a-treated animals. *P < 0:05;
**P < 0:01 vs. control (Student’s t test).
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role for Kir2.1 in muscle and brain may diﬀer. In this context,
the CNS responds to acute inﬂammation diﬀerently from other
body tissues. In fact, calcium channels are regulated diﬀeren-
tially in cardiac and neuronal cells [31]. Moreover, evidence
indicates that unlike other well-known neurological disorders
[3], the heart dysfunction that initiates with the syndrome may
be peripheral [1].
Since plasma TNF-a levels increased during experimental
cancer cachexia and may be responsible for impaired KCh
expression in brain, we performed a set of experiments in-
jecting TNF-a to rats. Previous studies from our group have
clearly indicated that this chronic TNF-a administration
mimics most of the metabolic alterations formed during ex-
perimental cancer cachexia. However, after 4 days of treat-
ment, animals develop tolerance to the cytokine (see [2] for
review). TNF-a diﬀerentially regulated Kv1.3 and Kir2.1
channels in brain (Fig. 3). In contrast to cancer cachexia, while
Kir2.1 expression decreased, Kv1.3 was upregulated. These
results may be interpreted taking into consideration certain
key diﬀerences between the two models. Thus, while experi-
mental cancer cachexia is a non-reversible situation in which
brain cells undergo apoptosis [6], the increase in plasma TNF-
a by chronic administration of the cytokine may be reversible,
as it is during infection. Moreover, Kþ channel expression is
impaired in the brain during experimental cancer cachexia, andanimals lose weight and develop anorexia [6]. In addition,
some Kþ channel gene knockout mice lost body weight and
showed altered feeding behavior [32,33]. However, chronic
TNF-a administration does not aﬀect food intake or body
mass [18]. Other factors may explain the discrepancy between
these two models. Thus, during experimental induced cancer-
cachexia, the long term increase in plasma TNF-a could de-
sensitize TNF-a receptors or upregulate the soluble forms of
the receptor (sTNFR). In fact, high plasma levels of sTNFR
have been found in patients with advanced gastrointestinal
cancer and sTNFR is an agonist of TNF-a that could prevent
some cytokine eﬀects [34–37].
TNF-a is produced by lymphocytes and macrophages in
response to an insult [20]. Within the brain, not only microglia
but also activated leukocytes generate TNF-a locally [3]. As a
result, there is an inﬂammatory response similar to that de-
scribed in AIDS patients in which TNF-a expression correlates
with the degree of dementia [38]. Few in vitro studies have
reported diﬀerential Kþ channel regulation by TNF-a in nerve
cells, with controversial results, e.g., enhanced, unaltered and
reduced outward and inward Kþ currents [11–14]. However,
the proteins responsible have not been identiﬁed. In addition, a
diﬀerential Kv1.3 and Kir2.1 regulation by TNF-a in the brain
is not surprising. In fact, our results agree with those described
in bone marrow and brain macrophages [15,39].
During an infection, LPS is one of the strongest activators of
macrophages and leads to the secretion of TNF-a. The gen-
eration of this and other cytokines such as IL-1b, IL-6 and IL-
12 leads to a rapid systemic inﬂammatory response in the host.
As mentioned above, LPS administration increases the sys-
temic TNF-a concentration (Fig. 1). Despite the amount of
information on how LPS aﬀects KCh in in vitro studies
[15,40,41], there are few in vivo studies. Exposure to sub-lethal
doses of LPS evokes a systemic inﬂammatory response that
includes fever and increased oxygen consumption similar to
that described in certain types of cancer [21]. In acute in-
ﬂammatory response, KCh were diﬀerentially regulated
(Fig. 4). Kv1.3 expression was induced, whereas Kir2.1 was
downregulated as observed with TNF-a. Several LPS eﬀects
are mediated by the production of TNF-a. Bearing this in
mind, we aimed to test whether this modulation depended on
the cytokine. For this purpose, we used TNF-a RI/II-KO mice,
which received an acute LPS injection as mentioned above.
While Kv1.3 upregulation was TNF-a-dependent, Kir2.1
modulation was independent (Fig. 4). These results are in
agreement with those described using macrophages, which
indicate that the LPS modulation of Kir2.1 is independent of
TNF-a, whereas Kv1.3 regulation could be partially dependent
[15]. However, TNF-a may also promote physiological eﬀects
by pathways independent of TNF-a receptors via its lectin
binding domain [42,43]. This possibility was tested by injecting
TNF-a into wild-type and TNF-a RI/II-KO mice. This treat-
ment, which generates important metabolic alterations [22–24],
did not modify KCh expression in the brain of TNF-a RI/II-
KO mice. However, the eﬀects in wild-type animals were
similar to those found with LPS (data not shown). Taken to-
gether, these data suggest that LPS involves TNF-a-dependent
and -independent redundant mechanisms in a number of cases.
In fact, not only KCh but also nucleoside transport regulation
may require this mode of action [44]. In addition, LPS-induced
apoptosis involves TNF-a as an early step followed by in-
duction of nitric oxide synthase [20]. In this regard, cancer may
Fig. 4. Expression of Kv1.3 and Kir2.1 in brain from LPS-treated animals. At least ﬁve C57BL/6 wild type (+/+) or TNF-a receptor I/II double
knockout ()/)) mice were administered intraperitoneally with either saline ()) or 2.5 mg/kg LPS (+). Animals were kept at thermoneutral tem-
perature (30 C) and samples were collected 23 h after LPS injection. (A) Kir2.1 and Kv1.3 mRNA expression. Results from RT-PCR on 0.25 lg and
30 cycles for Kir2.1 and Kv1.3, and 0.1 lg and 10 cycles for 18S are shown. These conditions were at the exponential phase of the amplicon
production as described in Section 2. Representative blots are shown. (B) Kir2.1 and Kv1.3 mRNA expression values derived from panel A. (C)
Kir2.1 and Kv1.3 Western blot analysis. Representative blots are shown. (D) Kir2.1 and Kv1.3 protein expression values derived from panel C. In all
cases, arbitrary units are standardized to the control value in the absence of LPS ()). Values are meansS.E.M. of at least four animals. Closed bars,
control; open bars, LPS-treated animals. No signiﬁcant diﬀerences were found between wild type (+/+) and TNF-a receptor I/II double knockout
()/)) mice in the absence of TNF-a ()). *P < 0:05; **P < 0:01; ***P < 0:001; ns, not signiﬁcant vs. control (Student’s t test).
R. Vicente et al. / FEBS Letters 572 (2004) 189–194 193induce oxidative stress within the brain, which has been related
to the appearance of neurological disorders [45]. Once cytokine
production is activated within the brain, paracrine and auto-
crine interactions can sustain local cytokine production
through positive-feedback systems [3].
In summary, the systemic inﬂammatory response may be
responsible for KCh regulation in brain. Blood TNF-a levels
during the endotoxic shock may trigger a ﬁnely tuned modu-
lation of KCh in the neurological response. Moreover, re-
dundant TNF-a-dependent and -independent mechanisms are
probably involved. The apparent discrepancy between infec-
tion and experimental cancer cachexia is not an irrelevant is-
sue. On the contrary, it is indicative of quite diﬀerent catabolic
conditions. Upon experimental cancer cachexia, brain cells
undergo apoptosis [6], which leads to neurotoxicity and neu-
rodegeneration [3]. In contrast, acute inﬂammation caused by
LPS may induce various responses within the brain that may
lead to distinct neurological disfunctions.
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